

## CURRICULUM VITAE

Il sottoscritto/a Dr Francesco Perri, ai sensi degli art.46 e 47 DPR 445/2000, consapevole delle sanzioni penali previste dall'art.76 del DPR 445/2000 e successive modificazioni ed integrazioni per le ipotesi di falsità in atti e dichiarazioni mendaci, dichiara sotto la propria responsabilità:

Nome	Francesco Perri
Indirizzo	
Telefono	
E-mail	
Data di nascita	NAPOLI, IL

### ESPERIENZA LAVORATIVA E PROFESSIONALE

• Date (da – a)

- Dal 30/7/2021 Riconoscimento incarico di COORDINATORE Gruppo Oncologico Multidisciplinare Tumori Testa-Collo.
- :Dal 01/6/2020 conferimento incarico professionale di “Referente Aziendale per la Formazione (RAF)
- Dal 20/2/2020 conferimento di Incarico di “referente Macroarea 1 (prevenzione primaria e secondaria) di ricerca”, presso l'INT IRCCS G. Pascale.
- Dal 21/2/2020 conferimento di Incarico di alta specializzazione dal nome: *il ruolo della ricerca traslazionale nel campo delle neoplasie del distretto cervico-cefalico.*
- *Dal 1/7/2019 Riconoscimento anzianità di servizio superiore ad anni 5*
- Dal 16 Aprile 2018 alla data attuale: Dirigente Medico di I livello presso l'INT IRCCS G. Pascale di Napoli, Dipartimento di Oncologia Testa Collo.
- Dal 1 Luglio 2014 al 15 Aprile 2018: Dirigente Medico di I livello presso Oncologia Medica dell'Ospedale “San Giuseppe Moscati” di Taranto
- Dal 05 Agosto 2013 al 18 Giugno 2014: Assistente in Formazione presso la Scuola di Specializzazione in Radioterapia, Università degli Studi di Napoli “Federico II”, Napoli
- Gennaio-Aprile 2012: Medico presso Centro Dialisi DYAL 3 Arzano
- Febbraio 2009 al 31 Luglio 2013: contratto di collaborazione esterna in qualità di Oncologo Medico presso L'Unità di Oncologia Medica Testa-Collo del Dipartimento Melanoma, Tessuti Molli e Testa-Collo dell'Istituto Tumori di Napoli, Fondazione “G. Pascale”.
- Marzo-Aprile 2008: Pronto Soccorso presso la Clinica “Villa dei Fiori” di Acerra (NA).
- Luglio 2005 – Gennaio 2009: Specializzazione in Oncologia presso il

Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica, Università degli Studi di Napoli "Federico II"

- Marzo 2003 - Luglio 2005: Studente Interno presso il Dipartimento di Radiodiagnostica e Radioterapia, Università degli Studi di Napoli "Federico II"
- Settembre 2002 – Marzo 2003: Studente Interno presso il Dipartimento di Ematologia dell'Università degli Studi di Napoli "Federico II"

## ISTRUZIONE E FORMAZIONE

Date (da – a)

- Dal 5/8/2013 al 19/6/2014: assistente in formazione presso la Scuola di Specializzazione in Radioterapia, Università degli Studi di Napoli "Federico II"
- 16-01-2009: Specializzazione in Oncologia Medica presso l'Università degli Studi di Napoli "Federico II", votazione 70/70 e lode
- Febbraio 2005: Abilitazione Professionale in Medicina e Chirurgia con votazione 265.25/270
- 26-07-2004: Laurea in Medicina e Chirurgia, Università degli Studi di Napoli, "Federico II", con votazione 110/110 e lode.
- 1998: Maturità Scientifica, Liceo "E. Torricelli", Somma Vesuviana (NA).

## Capacità e Competenze Personali

### Gestione e conduzione di studi clinici controllati secondo le regole di GCP

- A phase II dose-finding study of induction Cis-platin, Docetaxel and escalating dose of capecitabine followed by concurrent cetuximab and radiotherapy in locally advanced inoperable head and neck squamous cell carcinoma (**DOXERT 1**) (**Principal Investigator**)
- Panitumumab with Cisplatin and 5-FU as first line treatment of recurrent or metastatic SCCHN: the phase III **SPECTRUM** study (**Sub-I**)
- Cilengitide added to Cisplatin-Fluorouracil and Cetuximab for Recurrent/Metastatic SCCHN: phase III **ADVANTAGE** trial (**Sub-I**)
- AFATINIB versus placebo in patients with locally advanced head and neck cancer treated with chemo-radiotherapy. **1200.131** (**Sub-I**)
- AFATINIB versus Methotrexate as second line treatment in patients with Recurrent/Metastatic SCCHN. **1200.43** (**Sub-I**)
- Vandetanib versus placebo in patients with radically resected medullary thyroid cancer. **D4200C00097** (**Sub-I**)
- Combretastatin A4 plus Carboplatin-Paclitaxel in patients with anaplastic thyroid cancer (**Sub-I**)
- Study **EGF102988**, Glaxo-SmithKline. A randomized, double-blind, placebo-controlled, multicentre, phase III study of post-operative adjuvant Lapatinib or placebo and concurrent chemoradiotherapy followed by maintenance Lapatinib or placebo monotherapy in high-risk subjects with resected squamous cell carcinoma of the head and neck (SCCHN) (**Sub-I**)
- **Vandetanib** versus placebo in patients with Recurrent medullary thyroid carcinoma (**Sub-I**)
- Electrochemotherapy as a First Line Treatment in Recurrent

Squamous Cell Carcinoma of the Oral Cavity and Oropharynx  
PDL-1 negative and/or with evident contraindication to immunotherapy: A Randomized Controlled Trial. Sub-Inv

- Cisplatin-Paclitaxel and Cetuximab as first line chemotherapy in Recurrent/Metastatic SCCHN. **(Sub-I)**
- Protocol **CS001P3**: A Phase III, Open-Label Randomized, Multi-center Study of the Effects of Leukocyte Interleukin [Multikine]Plus Standard of Care (Surgery+Radiotherapy or Surgery + Concurrent Chemoradiotherapy)in Subjects with Advanced Primary Squamous Cell Carcinoma of the Oral Cavity/Soft Palate Versus Standard of Care. **(Sub-I)**
- Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-**CHANCE** trial. **(Sub-I)**
- Phase III trial comparing Ipilimumab plus Nivolumab vs EXTREME as first line treatment in SCCHN (Bristol Meyers Squibb). **(Sub-I)**
- **Protocol MK3475-630** “A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Pembrolizumab versus Placebo as Adjuvant Therapy Following Surgery and Radiation of High-Risk Locally Advanced Cutaneous Squamous Cell Carcinoma” **(Sub-I)**
- Phase III trial comparing cisplatin-Radiotherapy and Avelumab vs cisplatin radiotherapy in patients with locally advanced SCCHN. Pfizer and Merck Serono. **(Sub-I)**
- Phase III trial comparing cisplatin-Radiotherapy vs cisplatin-Radiotherapy and Pembrolizumab in locally advanced SCCHN, Merck Sharp and Domme. **(Sub-I)**
- Study of Nivolumab as second line treatment in patients with platinum refractory SCCHN. NIVACTOR trial. **(Sub-I)**
- **Protocol WO40242** “A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab (ANTI-PD-L1ANTIBODY) as Adjuvant Therapy after Definitive Local Therapy in Patients with High Risk Locally Advanced Squamous Cell Carcinoma of Head and Neck ” **(Sub-I)**
- Protocol 1559-HNCG EORTC “A pilot study of personalized biomarker-based treatment strategy or immunotherapy in patients with recurrent/metastatic squamous cell carcinoma of the head and neck” – UPSTREAM **(Sub-I)**
- Protocol XL184-311 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects with Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed after Prior VEGFR-Targeted Therapy **(Sub-I)**
- Protocol KO-TIP-007 A Pivotal Study of Tipifarnib in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS mutations who have Failed At least One Prior Line of Therapy **(Sub-I)**
- A phase III trial exploring Atezolizumab plus chemoradiation in patients with locally advanced SCCHN. Roche Study. **(Sub-I)**
- An Observational Study assessing analysis of biomarkers as predictive of response in patients with locally advanced SCCHN treated with cisplatin-RT (APACHE). **(Principal Investigator)**

- The BROADEN study - Observational study to assess the absolute Burden Of hpv-related head and neck cancers. **Principal Investigator**
  - Long-term survivors to immunotherapy in recurrent/metastatic head and neck cancer: a genomic landscape approach to identify predictive biomarkers (LTS). **Principal Investigator**
  - Cetuximab plus Monalizumab vs cetuximab and placebo in recurrent/metastatic SCCHN after failure of a first line containing check-point inhibitors. **INTERLINK study. Principal Investigator**
  - **BURAN** clinical study of Buparlisib (AN2025) in combination with Paclitaxel versus Paclitaxel alone, in patients with relapsed or metastatic squamous cell carcinoma of the head and neck. **Principal Investigator**
  - ISA Randomized, double-blind, placebo-controlled phase 2 study evaluating cemiplimab versus the combination of cemiplimab and ISA101b in the treatment of subjects with HPV16-positive oropharyngeal carcinoma (OPC). **Principal Investigator**
  - A randomized, double-blind placebo-controlled, Phase 3 study of Debio 1143 in combination with platinum-based chemotherapy and standard fractionation intensitymodulated radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck, suitable for definitive chemoradiotherapy (TrilynX). **Principal Investigator**
  - Pembrolizumab and Olaparib in relapsed / metastatic, platinum-resistant nasopharyngeal cancer **POINT Principal Investigator**
  - LA-HN Italy: a study to describe the diagnostic and therapeutic scenario of patients with locally advanced HNSCC (**LA-HNSCC in Italy**) **Principal Investigator**
  - **PARTIFICIAL INTELLIGENCE FOR THE DEFINITION OF NEW SIGNATURES AND MODELS FOR THE CUSTOMIZATION OF THE ORGAN PRESERVATION STRATEGIES OF LARYNGEAL AND HYPOPHARYNGAL CANCER. PRESERVE. Principal Investigator**
- 
- **Ricerca Oncologia Traslazionale** Studio dei fattori clinici e biomolecolari prognostici e predittivi di risposta ai trattamenti oncologici (Chemio, Radio e Immunoterapia) nei pazienti affetti da neoplasie del testa-collo. Diversi papers pubblicati inerenti l'argomento, Progetti di Ricerca di cui è autore, PI di studi clinici spontanei ed organizzatore di eventi formativi.
  - **Elettrochemioterapia come trattamento palliativo delle metastasi cutanee e linfonodali da tumori della cute e del testa-collo**
  - Co-operatore in più di 100 interventi di Elettrochemioterapia, autore di diversi papers pubblicati inerenti l'argomento, nonché sub-investigators in studi clinici multicentrici

### **Immunoterapia**

- Organizzatore di eventi scientifici, sub-Investigatore di diversi studi

clinici multicentrici, organizzatore di eventi formativi ed autore di diversi papers inerenti l'argomento

- **Radioterapia Oncologica**

Assistente in formazione presso Scuola di Specializzazione ed autore di diversi papers pubblicati

- **Gestione della terapia del dolore nel paziente oncologico**

Esperienza clinica, monografie e papers pubblicati e corsi di formazione specifici

- **Emodialisi extracorporea**

- Pregresso impiego lavorativo presso Centro di Dialisi Accreditato

**Conoscenza Lingue:**

Italiano ed Inglese

**Pubblicazioni scientifiche in extenso**

1. The ubiquitin-proteasome system as a molecular target in solid tumors: an update on bortezomib.”

Milano A, **Perri F**, Caponigro F.

Onco Targets Ther. 2009 Feb 18;2:171-8

2. Docetaxel in the management of head and neck cancer”

Caponigro F, Longo F, **Perri F**, Ionna F.

Anticancer Drugs 2009; 20:639-45

3. Recent results of Cetuximab use in the treatment of squamous cell carcinoma of head and neck”

**Perri F**, Longo F, Ionna F, Caponigro F.

Onco Targets Ther. 2009 Feb 18;2:243-50

4. New treatment approaches in renal cell carcinoma”

Facchini G, **Perri F**, Caraglia M, Pisano C, Striano S, Marra L, Fiore F, Aprea P, Pignata S, Iaffaioli RV. Anticancer

Drugs. 2009 Nov;20:893-900

5. Treatment approaches to nasopharyngeal carcinoma: a review”

Caponigro F, Longo F, Ionna F, **Perri F**. Anticancer Drugs.

2010 Jun;21(5):471-7.

6. Pre-operative chemotherapy for colorectal cancer liver metastases: an update of recent clinical trials”

Nasti G, Ottaiano A, Berretta M, Delrio P, Izzo F, Cassata A, Romano C, Facchini G, Scala D, Mastro A, Romano G, **Perri F**, Iaffaioli RV.

Cancer Chemother Pharmacol. 2010 Jul;66:209-18

7. Anaplastic thyroid carcinoma: a comprehensive review of current and future therapeutic options”

**Perri F**, Lorenzo GD, Scarpati GD, Buonerba C.

World J Clin Oncol. 2011 Mar 10;2:150-7

8. Targeted-therapy and imaging response: a new paradigm for clinical evaluation?”

Milano A, **Perri F**, Ciarmiello A, Caponigro F.

Rev Rec Clin Trials 2011 Apr 19

9. Locally advanced nasopharyngeal carcinoma: Current and emerging treatment strategies

**Francesco Perri**, Davide Bosso, Carlo Buonerba, Giuseppe Di Lorenzo, Giuseppina Della Vittoria Scarpati World J Clin Oncol 2011 December 10; 2(12): 377-383

10. Integrated Therapeutic Approaches in Head and Neck Cancer: the Importance of Multidisciplinary Team Management.”

**Perri F**, Muto P, Aversa C, Daponte A, Della Vittoria Scarpati G, Pepe S, Caponigro F.

Anticancer Agents Med Chem. 2012 Nov 23.

11. Multidisciplinary Approach to Rectal Cancer: Are We Ready for Selective Treatment Strategies?”

Avallone A, Aloj L, Delrio P, Pecori B, Leone A, Tatangelo F, **Perri F**, Petrillo A, Scott N, Budillon A.

Anticancer Agents Med Chem. 2012 Dec 14.

12. Multidisciplinary Approach to Patient with Malignant Melanoma.

Della Vittoria Scarpati G, Fusciello C, Sabbatino F, Ferrone S, Caponigro F, **Perri F**, Carlomagno C, Pepe S. Anticancer Agents Med Chem. 2012 Dec 14

13. Calcitriol: a better option than vitamin D in denosumab-treated patients with kidney failure?”

Buonerba C, Caraglia M, Malgieri S, **Perri F**, Bosso D, Federico P, Ferro M, Rizzo M, Palmieri G, Di Lorenzo G. Expert Opin Biol Ther. 2013 Feb;13(2):149-1.

14. Induction Chemotherapy with Docetaxel, Cisplatin and Capecitabine, Followed by Combined Cetuximab and

Radiotherapy in Patients with Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck: A Phase I-II Study.” **Perri F**, Muto P, Argenone A, Ionna F, Longo F, Fulciniti F, Sandomenico F, Daponte A, Caponigro F. *Oncology*. 2013;84(4):251-4.

15. Induction Docetaxel-Cisplatin Followed by Extended-field Radiotherapy in Patients with Cervical Metastases from Unknown Primary Carcinoma”.

**Perri F**, Ionna F, Muto P, Buonerba C, Della Vittoria Scarpati G, Bosso D, Fulciniti F, Daponte A, Argenone A, Sandomenico F, DI Lorenzo G, Caponigro F. *Anticancer Res*. 2013 Mar;33(3):1135-9

16. Combined chemo-radiotherapy in locally advanced nasopharyngeal carcinomas.

**Francesco Perri**, Giuseppina Della Vittoria Scarpati, Carlo Buonerba, Giuseppe Di Lorenzo, Francesco Longo, Paolo Muto, Concetta Schiavone, Fabio Sandomenico, Francesco Caponigro  
*World J Clin Oncol* 2013 May 10; 4(5): 00-00

17. Non-AIDS-related Kaposi's sarcoma: A single-institution experience

Rescigno P, Di Trolio R, Buonerba C, De Fata G, Federico P, Bosso D, Virtuoso A, Izzo M, Policastro T, Vaccaro L, Cimmino G, **Perri F**, Matano E, Delfino M, De Placido S, Palmieri G, Di Lorenzo G.  
*World J Clin Oncol*. 2013 May 10;4(2):52-7.

18. Treatment approaches in elderly patients with head and neck cancer. **Perri F**, Ionna F, Pavone E, Longo F, Caponigro F.

*Anticancer Agents Med Chem*. 2013 Nov;13(9):1383-90.

19. The best partner for radiotherapy after induction chemotherapy in a larynx preservation strategy.

Della Vittoria Scarpati G, **Perri F**, Ricciardiello F, Napolitano D, Addeo R.  
*Oral Oncology* 50 (2014) e1–e2

20. Hyalinizing clear cell carcinoma of the parotid gland. Report of a recurrent case with aggressive cytomorphology and behavior diagnosed on Fine Needle Cytology sample.

Fulciniti F, Pia Curcio M, Liguori G, Aquino G, Botti G, Campanile AC, De Cecio R, Pavone E, Aversa C, **Perri F**, Caponigro F, Ionna F.  
*Diagn Cytopathol*. 2014 Jan;42(1):63-8.

21. Ipilimumab in the treatment of metastatic melanoma: management of adverse events.

Della Vittoria Scarpati G, Fusciello C, **Perri F**, Sabbatino

F, Ferrone S, Carlomagno C, Pepe S  
OncoTargets and Therapy 2014:7

22. Targeted therapy: a new hope for thyroid carcinoma.  
Caponigro F, Pezzullo L, Chiofalo MG, Lastoria S, Di  
Gennaro F, Della Vittoria Scarpati G, **Perri F**.

Crit Rev Oncol Hematol. 2014 Nov 1 pii: S1040-  
8428(14)00172-3

23. ASCO 2013: bevacizumab and glioblastoma - a  
marriage dissolution?

Addeo R, **Perri F**, Parlato C, Della Vittoria G.

Curr Med Res Opin. 2014 May 29:1-3.

24. HPV-related oropharyngeal cancers: From pathogenesis  
to new therapeutic approaches.

Tornesello ML, **Perri F**, Buonaguro L, Ionna F, Buonaguro  
FM, Caponigro F.

Cancer Lett. 2014 Jun 24.

25. Radioresistance in head and neck squamous cell  
carcinoma: Biological bases and therapeutic implications.

**Perri F**, Pacelli R, Della Vittoria Scarpati G, Cella L,  
Giuliano M, Caponigro F, Pepe S.

Head Neck. 2014 Jul 4.

26. Optimal management of a patient with recurrent  
nasopharyngeal carcinoma.

**Perri F**, Dell'Oca I, Muto P, Schiavone C, Aversa C,  
Fulciniti F, Solla R, Della Vittoria Scarpati G, Buonerba C,  
Di Lorenzo G, Caponigro F.

World J Clin Cases. 2014 Jul 16;2(7):297-300

27. Carboplatin plus etoposide in heavily pretreated  
castration-resistant prostate cancer patients. Buonerba C,  
Federico P, Bosso D, Puglia L, Policastro T, Izzo M, **Perri**

**F**, Della Vittoria Scarpati G, Ferro M, Cobelli OD, De  
Placido S, Aieta M, Imbimbo C, Longo N, Di Lorenzo G

Future Oncol. 2014 Jun;10(8):1353-60

28. Targeted therapy: A new hope for thyroid carcinomas.

**Perri F**, Pezzullo L, Chiofalo MG, Lastoria S, Di Gennaro  
F, Della Vittoria Scarpati G, Caponigro F.

Crit Rev Oncol Hematol. 2014 Nov 1pii: S1040-  
8428(14)00172-3.

29. The evolving landscape in advanced penile cancer.

Buonerba C, Di Lorenzo G, Calderoni G, Ferro M, **Perri F**,  
Lombardi L, Ardito R, Federico P, Placido S, Aieta M

Future Sci OA. 2015 Nov 1;1(3):FSO9.

30. adenoid cystic carcinoma of the lacrimal gland  
metastasizing after long follow-up to single dorsal

vertebrae: a case report and review of the literature. S. Pisconti, G. Favia, C. D'aniello, C. Cavaliere, F. Perri ,A. Licchetta, A. Gnoni. WCRJ 2014; 1 (4): e364

31. Adjuvant treatment in patients at high risk of recurrence of thymoma: efficacy and safety of a three-dimensional conformal radiation therapy regimen.

**Perri F**, Pisconti S, Conson M, Pacelli R, Della Vittoria Scarpati G, Gnoni A, D'Aniello C, Cavaliere C, Licchetta A, Cella L, Giuliano M, Schiavone C, Falivene S, Di Lorenzo G, Buonerba C, Ravo V, Muto P. *Onco Targets Ther.* 2015 Jun 8;8:1345-9.

32. Epstein-Barr virus infection and nasopharyngeal carcinoma: the other side of the coin. **Perri F**, Della Vittoria Scarpati G, Giuliano M, D'Aniello C, Gnoni A, Cavaliere C, Licchetta A, Pisconti S.

*Anticancer Drugs.* 2015 Aug 3

33. Brooke-Spiegler syndrome presenting multiple concurrent cutaneous and parotid gland neoplasms: cytologic findings on fine-needle sample and description of a novel mutation of the CYLD gene. Malzone MG, Campanile AC, Losito NS, Longo F, **Perri F**, Caponigro F, Schiavone C, Ionna F, Maiello F, Martinuzzi C, Nasti S, Botti G, Fulciniti F.

*Diagn Cytopathol.* 2015 Aug;43(8):654-8.

34. Role of translational research in squamous cell carcinoma of the head and neck: is it possible to improve the therapeutic scenario? **Perri F**, D'Aniello C, Cavaliere C, Russo F, Pisconti S, Facchini G, Taibi R, Della Vittoria Scarpati G.

*WCRJ* 2015; 2 (2): e520

35. How can we improve prognostic models in renal cell carcinoma?

Buonerba C, Ferro M, **Perri F**, Calderoni G, Mambella P, Giordano P, Piscitelli P, Montanaro V, Aieta M, Di Lorenzo G

*Expert Opin Pharmacother.* 2015 Jun;16(9):1281-3.

36. Concomitant cetuximab and radiation therapy: A possible promising strategy for locally advanced inoperable non-melanoma skin carcinomas. Della Vittoria Scarpati G, **Perri F**, Pisconti S, Costa G, Ricciardiello F, Del Prete S, Napolitano A, Carraturo M, Mazzone S, Addeo R.

*Mol Clin Oncol.* 2016 Apr;4(4):467-471. Epub 2016 Jan 27

37. Oral vinorelbine: a feasible and safe partner for radiotherapy in the treatment of locally advanced non-small cell lung cancer.

**Perri F**, Lazzari G, Della Vittoria Scarpati G, Silvano G.  
OncoTargets and Therapy 2016;9 2359–2364

38. Co-presentation of hypothermia and vanishing bile duct syndrome in Hodgkin's lymphoma: a case report and a brief review of the literature. Longo V, **Perri F**, Pisconti S, Della Vittoria Scarpati G, Buchicchio C, Ciuffreda L, De Santis G, Diomede D, Damiano Inchingolo C, D'Aniello C, Cavaliere C, Miccolis R M, Paqua Mongelli P, Santeramo TM, Tarantini G. WCRJ 2016; 3 (1): e637.

39. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.

Caponigro F, Di Gennaro E, Ionna F, Longo F, Aversa C, Pavone E, Maglione MG, Di Marzo M, Muto P, Cavalcanti E, Petrillo A, Sandomenico F, Maiolino P, D'Aniello R, Botti G, De Cecio R, Losito NS, Scala S, Trotta A, Zotti A, Bruzzese F, Daponte A, Calogero E, Montano M, Pontone M, De Feo G, **Perri F**, Budillon A. BMC Cancer. 2016 Nov 25;16(1):918.

40. Optimal multidisciplinary treatment of oral cavity mucosal melanoma: outcome analysis in a case series

**Perri F**, Pisconti S, Favia M, Della Vittoria Scarpati G, Conson M, Giuliano M, Ionna F, Longo F, Domenico B, Maiorano E, Favia G.

Anticancer Drugs. 2016 Dec 6.

41. Locally advanced paranasal sinus carcinoma: a study of 30 patients.

**Perri F**, Addeo R, Conson M, Faiella A, Della Vittoria Scarpati G, Torre G, Di Biase A, Romanelli P, Buonerba C, Di Lorenzo G, Daponte A, Caponigro F, Pisconti S, Pacelli R, Ravo V, Muto P and Solla R

Oncology Letters, 2017 Mar;13(3):1338-1342.

42. P53 mutations and cancer: a tight linkage. **Perri F**, Pisconti S, Della Vittoria Scarpati G. Ann Transl Med. 2016 Dec;4(24):522.

43. Metastatic HPV-related oropharyngeal carcinoma cured with chemoradiotherapy: Importance of pre-therapy biomolecular assessment. **Perri F**; Longo F; Della Vittoria Scarpati G; Pisconti S; Longo V; Addeo R; Carducci F; Buonerba C; Fulciniti F and Solla R. Clin Case Rep. 2017 Nov 24;6(1):56-62.

44. Epigenetic control of gene expression: Potential implications for cancer treatment. **Perri F**, Longo F, Giuliano M, Sabbatino F, Favia G, Ionna F, Addeo R, Della Vittoria Scarpati G, Di Lorenzo G, Pisconti S. Critical

Reviews in Oncology and Hematology (2017)

45. MELANOMA ADJUVANT TREATMENT: current insight and clinical features.

D'Aniello C, **Perri F**, Della Vittoria Scarpati G, Della Pepa C, Pisconti S, Montesarchio V, Wernert N, Zarone MR, Caraglia M, Facchini G1, Berretta M, Cavaliere C. *Curr Cancer Drug Targets*. 2017 Feb 8.

46. Optimal Management of Prostate Cancer Based on its Natural Clinical History.

Facchini G, **Perri F**, Misso G, D'Aniello C, Della Vittoria Scarpati G, Rossetti S, Della Pepa C, Pisconti S, Unteregger G, Cossu A, Caraglia M, Berretta M, Cavaliere C. *Curr Cancer Drug Targets*. 2017 Feb 8.

47. Vinflunine and bladder cancer: present and future indications

Della Vittoria Scarpati G, **Perri F**, Ferro M, Cavaliere C, Facchini G, Caraglia M, Zappavigna S, Addeo R. *Translational Medicine Reports* 2017; volume 1:6397

48. Single nucleotide polymorphisms and unacceptable late toxicity in breast cancer adjuvant radiotherapy: a case report. Lazzari G, Natalicchio MI, Terlizzi A, **Perri F**, Silvano G. *Breast Cancer (Dove Med Press)*. 2017 May 29;9:401-406

49. Predictive parameters in hypofractionated whole-breast 3D conformal radiotherapy according to the Ontario Canadian trial. Lazzari G, Terlizzi A, **Della Vittoria Scarpati G**, Perri F, De Chiara V, Turi B, Silvano G.

50. Benign leiomyoma metastasizing to the lung: a case report and a brief review of the literature. Grazia Lazzari, **Francesco Perri**, Giuseppina della Vittoria Scarpati, Salvatore Pisconti, Giovanni Silvano. *Journ of unexpl med data*. DOI:10.20517/2572-8180.2017.06

51. Translational research for Hepatocellular Carcinoma: What's new? Gnoni A, Pisconti S, Della Vittoria Scarpati G, Licchetta A, Silvestriis N, Giuliano M, **Perri F** and Giordano A. *Translational Medicine Reports*. Oct 30, 2017.

52. Metastatic HPV-related oropharyngeal carcinoma cured with chemoradiotherapy: importance of pretherapy biomolecular assessment. **Perri F**, Longo F, Della Vittoria Scarpati G, Pisconti S, Longo V, Addeo R, Carducci F, Buonerba C, Fulciniti F and Solla R. *Clin Case Rep*. 2017 Nov 24;6(1):56-62.

53. Translational Research in Cutaneous Melanoma: New

Therapeutic Perspectives. Marra A, Ferrone CR, Fusciello C, Scognamiglio G, Ferrone S, Pepe S, **Perri F**, Sabbatino F. *Anticancer Agents Med Chem.* 2018;18(2):166-181.

54. The Impact of Translational Research in Breast Cancer Care: Can we Improve the Therapeutic Scenario? Buono G, Schettini F, **Perri F**, Arpino G, Bianco R, Criscitiello C, De Placido S, Giuliano M. *Anticancer Agents Med Chem.* 2018;18(6):832-836.

55. Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-Line Sunitinib (QUASAR): Results of a Phase I Trial. Buonerba C, De Placido P, Bruzzese , Pagliuca M, Ungaro P, Bosso D, Ribera D, Iaccarino S, Scafuri L, Liotti A, Romeo V, Izzo M, **Perri F**, Casale B, Grimaldi G, Vitrone F, Brunetti A, Terracciano D, Marinelli A, De Placido S, Di Lorenzo G. *Front Pharmacol.* 2018 Mar 16;9:189.

56. Translational research: a future strategy for managing Squamous Cell Carcinoma of the Head and Neck? **Perri F**, Ionna F, Scarpati GDV, Longo F, Addeo R, Manzo R, Muto P, Pisconti S, Leopaldi L, Caponigro F. *Anticancer Agents Med Chem.* 2018 Apr 10.

57. Thyroid cancer management: from a suspicious nodule to targeted therapy. **Perri F**, Giordano A, Pisconti S, Ionna F, Chiofalo MG, Longo F, Leopardo D, Della Vittoria Scarpati G, Pezzullo L. *Anticancer Drugs.* 2018 Jul;29(6):483-490.

58. Effective nivolumab sequential thoracic radiotherapy in elderly patients with advanced squamous cell lung cancer: did radiation therapy play a role? A case report. Lazzari G, Terlizzi A, Porrazzo G, Devicienti S, **Perri F**, Della Vittoria Scarpati G, Silvano G. *Onco Targets Ther.* 2018 Aug 7;11:4621-4629.

59. The evolving landscape of immunotherapy against cancer. Pisconti S., Della Vittoria Scarpati G., Facchini G., Cavaliere C., D'Aniello C., Friscinni A., Melissano A., Bellini E., **Perri F**. *WCRJ* 2018; 5 (1): e1042.

60. Genetics and management of locally advanced carcinomas of the head and neck: role of altered fractionation radiotherapy. **Francesco Perri** , Franco Ionna , Paolo Muto , Massimiliano Di Marzo, Francesco Caponigro, Francesco Longo, Giuseppina Della Vittoria Scarpati, Giuseppe Di Lorenzo, Mario Giuliano& Raffaele Solla. *Future Science.* 26 Oct 2018<https://doi.org/10.4155/fsoa-2018-0058>.

61. Clinical management of localized undifferentiated sinonasal carcinoma (SNUC): our experience and review of the literature. **Perri F**, Della Vittoria Scarpati G, Ionna F, Longo F, Montano M, Muto P, Ravo V, Giuliano M, and Caponigro F. *Anticancer Drugs* 2018 2019 Mar;30(3):308-312

62. Management of recurrent nasopharyngeal carcinoma: current perspectives. **Perri F**, Della Vittoria Scarpati G, Caponigro F, Ionna F, Longo F, Buonopane S, Muto P, Di Marzo M, Pisconti S, Solla R. *Onco Targets Ther.* 2019 Feb 26;12:1583-1591.

63. Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumor. Ferro M, Di Lorenzo G, Vartolomei MD, Bruzzese D, Cantiello F, Lucarelli G, Musi G, Di Stasi S, Hurle R, Guazzoni G, Busetto GM, Gabriele A, Del Giudice F, Damiano R, **Perri F**, Perdona S, Verze P, Borghesi M, Schiavina R, Almeida GL, Bove P, Lima E, Autorino R, Crisan N, Farhan ARA, Battaglia M, Russo GI, Ieluzzi V, Morgia G, De Placido P, Terracciano D, Cimmino A, Scafuri , Mirone V, De Cobelli O, Shariat S, Sonpavde G, Buonerba C. *World J Urol.* 2019 Apr 16.

64. Electrochemotherapy as palliative treatment in patients with advanced head and neck tumours: Outcome analysis in 93 patients treated in a single institution. Longo F, **Perri F**, Pavone E, Aversa C, Maglione MG, Guida A, Montano M, Villano S, Daponte A, Caponigro F, Ionna F. *Oral Oncol.* 2019 May;92:77-84.

65. Oral lichen planus and other confounding factors in narrow band imaging (NBI) during routine inspection of oral cavity for early detection of oral squamous cell carcinoma: a retrospective pilot study. Guida A, Maglione M, Crispo A, **Perri F**, Villano S, Pavone E, Aversa C, Longo F, Feroce F, Botti G, Ionna F. *BMC Oral Health.* 2019 Apr 30;19(1):70.

66. Immune response against Head and Neck Cancer: biological mechanisms and implication on therapy. **Francesco Perri**; Franco Ionna; Francesco Longo; Giuseppina Della Vittoria Scarpati; Carmine De Angelis; Alessandro Otaiano; Gerardo Botti and Francesco Caponigro. *Translational Oncology* 2020.

67. Management of Ewing Sarcoma family of Tumors: a short description of a rare uterine primitive and literature review. Pisconti Salvatore, Della Vittoria Scarpati Giuseppina, Buonerba Carlo, Messinese Simona, Carella

Roberta, Di Marzo Massimiliano, Di Lorenzo Giuseppe, Lazzari Grazia, **Perri Francesco** and Solla Raffaele. *Oncotarget and Therapy*. 2020 Feb 14;13:1179-1184.

68. Ottaiano A, Circelli L, Lombardi A, Scala S, Martucci N, Galon J, Buonanno M, Scognamiglio G, Botti G, Hermitte F, Savarese G, D'Amore L, Tatangelo F, Di Mauro A, Liguari G, Trotta AM, Napolitano M, Capozza M, Tafuto S, **Perri F**, La Rocca A, Caraglia M, Nasti G. Genetic trajectory and immune microenvironment of lung specific oligometastatic colorectal cancer. *Cell Death Dis*. 2020 Apr 24;11(4):275.

69. **Francesco Perri** \*, Francesco Longo , Francesco Caponigro , Fabio Sandomenico , Agostino Guida , Giuseppina Della Vittoria Scarpati , Alessandro Ottaiano Paolo Muto and Franco Ionna. Management of HPV-Related Squamous Cell Carcinoma of the Head and Neck: Pitfalls and Caveat. *Cancers (Basel)*. 2020 Apr 15;12(4).

70. Longo F, **Perri F**, Caponigro F, Della Vittoria Scarpati G, Guida A, Pavone E, Aversa C, Muto P, Giuliano M, Ionna F, Solla R. Boosting the Immune Response with the Combination of Electrochemotherapy and Immunotherapy: A New Weapon for Squamous Cell Carcinoma of the Head and Neck? *Cancers (Basel)*. 2020 Sep 28;12(10):E2781.

71. Crispo A, Montagnese C, **Perri F**, Grimaldi M, Bimonte S, Augustin LS, Amore A, Celentano E, Di Napoli M, Cascella M, Pignata S. COVID-19 Emergency and Post-Emergency in Italian Cancer Patients: How Can Patients Be Assisted? *Front Oncol*. 2020 Aug 11;10:1571.

72. Grazia Lazzari, **Perri Francesco**, Giuseppina Scarpati Della Vittoria, Maria Giovanna Monis, Giovanna Porrizzo, Giovanni Silvano. Electron beam radiotherapy in giant non-melanoma skin cancers of the head in elderly inoperable patients: a single centre retrospective study. *Journal of Cancer Prevention & Current Research*. Volume 11 Issue 4 – 2020.

73. Ottaiano A, Caraglia M, Di Mauro A, Botti G, Lombardi A, Galon J, Luce A, D'Amore L, **Perri F**, Santorsola M, Hermitte F, Savarese G, Tatangelo F, Granata V, Izzo F, Belli A, Scala S, Delrio P, Circelli L, Nasti G. Evolution of Mutational Landscape and Tumor Immune-Microenvironment in Liver Oligo-Metastatic Colorectal Cancer. *Cancers (Basel)*. 2020 Oct 21;12(10):E3073.

74. Salzano G, Maglitto F, Guida A, **Perri F**, Maglione MG, Buonopane S, Muto P, Ionna F. Surgical oncology of the head and neck district during COVID-19 pandemic.

Surgical oncology of the head and neck district during COVID-19 pandemic.

Salzano G, Maglitto F, Guida A, Perri F, Maglione MG, Buonopane S, Muto P, Ionna F.

Eur Arch Otorhinolaryngol. 2021 Jan 4:1-5.

75. **Francesco Perri**, Agostino Guida; Giovanni Salzano ; MariaGrazia Maglione; Fabio Maglitto; Sergio Buonopane; Roberto Manzo;Francesco Caponigro; Paolo Muto and Franco Ionna. Management of Squamous Cell

Carcinoma of the Head and Neck:

what has changed and what we can add. Civitas Hippocratica. Ricevuto in Redazione il 25 settembre 2020.

76. Guida A, **Perri F**, Ionna F, Ascierio PA, Grimaldi AM. New-generation anticancer drugs and medication-related osteonecrosis of the jaw (MRONJ): Late onset 3 years after ipilimumab endovenous administration with a possible role of target therapy. Clin Case Rep. 2020 Dec 2;9(1):61-66.

77. Ottaiano A, Scala S, Santorsola MC **Perri F**....et al. Aflibercept or bevacizumab in combination with FOLFIRI as second-line treatment of mRAS metastatic colorectal cancer patients: the ARBITRATION study protocol. Ther Adv Med Oncol. 2021 Mar 24;13:

78. Ottaiano A, Nasti G, Santorsola MC, **Perri F**....et al. KRAS Mutational Regression Is Associated With Oligo-Metastatic Status and Good Prognosis in Metastatic Colorectal Cancer. Front in Oncol. Front Oncol. 2021 Mar 29;11:632962.

79. **Perri F**, Crispo A, Ionna F, et al. Patients affected by squamous cell carcinoma of the head and neck: A population particularly prone to developing severe forms of COVID-19Exp Ther Med. 2021 Nov;22(5):1298.

80. **Perri F\***, Carella R\*, Caponigro F, Longo F, Della Vittoria Scarpati G, Marciano M, Pontone M, Esposito G, Ionna F, Muto P, Buonopane S, Ottaiano A, Cuomo A, Cascella M. Clinical features and multidisciplinary management of cancer-associated pain (CAP). A narrative review. Terapia Evidence Based 2020; Vol. XIII, N. 1, marzo 2020.

81. **Perri F**, Longo F, Fusco R, D'Alessio V, Aversa C, Pavone E, Pontone M, Marciano ML, Villano S, Franco P, Togo G, Fazio GR, Ordano D, Maglitto F, Salzano G, Maglione MG, Guida A, Ionna F. Electrochemotherapy as a First Line Treatment in Recurrent Squamous Cell Carcinoma of the Oral Cavity and Oropharynx PDL-1

Negative and/or with Evident Contraindication to Immunotherapy: A Randomized Multicenter Controlled Trial. *Cancers (Basel)*. 2021 May 4;13(9):2210.

82. Ionna F, Bossi P, Guida A, Alberti A, Muto P, Salzano G, Ottaiano A, Maglitto F, Leopardi D, De Felice M, Longo F, Tafuto S, Della Vittoria Scarpati G, **Perri F**. Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: A Big and Intriguing Challenge Which May Be Resolved by Integrated Treatments Combining Locoregional and Systemic Therapies. *Cancers (Basel)*. 2021 May 14;13(10):2371.

83. Ottaiano A, Santorsola M, Del Prete P, **Perri F**, Scala S, Caraglia M, Nasti G. Prognostic Significance of CXCR4 in Colorectal Cancer: An Updated Meta-Analysis and Critical Appraisal. *Cancers (Basel)*. 2021 Jun 30;13(13):3284.

84. Bracigliano A, Tatangelo F, **Perri F**, Di Lorenzo G, Tafuto R, Ottaiano A, Clemente O, Barretta ML, Losito NS, Santorsola M, Tafuto S. Malignant Sinonasal Tumors: Update on Histological and Clinical Management. *Curr Oncol*. 2021 Jul 1;28(4):2420-2438.

85. **Perri F** et al. Addendum: Electrochemotherapy as a First Line Treatment in Recurrent Squamous Cell Carcinoma of the Oral Cavity and Oropharynx PDL-1 Negative and/or with Evident Contraindication to Immunotherapy: A Randomized Multicenter Controlled Trial. *Cancers* 2021,13, 2210.

86. The Art of Counselling in the Treatment of Head and Neck Cancer: Explorative Investigation Among Perceptions of Health Professionals in Southern Italy. Addeo R, Bocchetti M, Perri F et al. DOI: 10.21203/rs.3.rs-589953/v1. July 2021.

87. Maglitto F, Committeri U, **Perri F** et al. Quantitative assessment of dimensional evolution of solitary osteoma of the mandible through 14 years of radiographic follow-up analysis: A unique case report. *May 2021 Oral and Maxillofacial Surgery Cases* 7(10):10021.

88. **Perri F**, Della Vittoria Scarpati G, Carella R, Ottaiano A, Cascella M et al. Emergencies in oncology: An overview and practical suggestions. *Recenti Prog Med*. 2021 Oct;112(10):627-638.

89. Lauricella E, Cives M, Bracigliano A, Clemente O, **Perri F** et al. "THE PSYCHOLOGICAL IMPACT OF COVID-19 PANDEMIC ON PATIENTS WITH

NEUROENDOCRINE TUMORS: BETWEEN RESILIENCE AND VULNERABILITY".Journal of Neuroendocrinology. July 2021. INPRESS.

90. Fasano M, **Perri F**, Della Corte CM, Di Liello R, Della Vittoria Scarpati G, Cascella M, Ottaiano A, Ciardiello F, Solla R. Translational Insights and New Therapeutic Perspectives in Head and Neck Tumors. Biomedicines. 2021 Aug 19;9(8):1045.

91. Ottaiano A, Petito A, Santorsola M, Gigantino V, Capuozzo M, Fontanella D, Di Franco R, Borzillo V, Buonopane S, Ravo V, Scipilliti E, Totaro G, Serra M, Ametrano G, Penta R, Tatangelo F, Scognamiglio G, Di Mauro A, Di Bonito M, Napolitano M, Scala S, Rea G, Santagata S, Lombardi A, Grimaldi A, Caputo C, Crispo A, Celentano E, De Feo G, Circelli L, Savarese G, Ruggiero R, **Perri F**, Granata V, Botti G, Caraglia M, Nasti G, Muto P. Prospective Evaluation of Radiotherapy-Induced Immunologic and Genetic Effects in Colorectal Cancer Oligo-Metastatic Patients with Lung-Limited Disease: The PRELUDE-1 Study. Cancers (Basel). 2021 Aug 23;13(16):4236.

92. Fabio Maglitto , Giovanni Salzano , Francesco Longo , Elio Di Bernardo , Valeria D'Alessio , Roberta Fusco , Corrado Aversa , Ettore Pavone , Monica Pontone , Maria Luisa Marciano , Giulia Togo , Gianluca Renato De Fazio , Daniele Ordano , Maria Grazia Maglione , Luigi Angelo Vaira , Michela Bergonzani, Francesco Antonio Salzano , Piera Maiolino , Luigi Califano , Franco Ionna and **Francesco Perri**. Electrochemotherapy as Palliative Treatment in Patients with Recurrent and/or Metastatic Head and Neck Tumours: Features Analysis for an Early Determination of the Partial Responsive Patients. Medical and Pharmacological Sciences. Nov 2021. IN PRESS

93. Tamara Zec, Raffaella Di Napoli Lydwine Fievez Mohammed Ben Aziz Alessandro Ottaiano, Alessandro Vittori, **Francesco Perri**, Marco Cascella. Efficacy and safety of tranexamic acid in cancer surgery. An update of clinical findings and ongoing research. Journ of Mult Healthcare. Nov 2011. IN PRESS

94. Ottaiano A, Circelli L, Santorsola M, Savarese G, Fontanella D, Gigantino V, Di Mauro A, Capuozzo M, Zappavigna S, Lombardi A, Perri F, Cascella M, Granata V, Capuozzo M, Nasti G, Caraglia M. Metastatic colorectal cancer and type 2 diabetes: prognostic and genetic interactions. Mol Oncol. 2021 Oct 20.

95. Giovanni Salzano , Francesco Perri , Fabio Maglitto , Giulia Togo , Gianluca Renato De Fazio , Michela Apolito , Federica Calabria , Claudia Laface , Luigi Angelo Vaira , Umberto Committeri , Mario Balia 5 , Ettore Pavone , Corrado Aversa , Francesco Antonio Salzano , Vincenzo Abbate , Alessandro Ottaiano , Marco Cascella , Mariachiara Santorsola , Roberta Fusco , Luigi Califano and Franco Ionna . Pre-Treatment Neutrophil-to-Lymphocyte and Platelet-toLymphocyte Ratios as Predictors of Occult Cervical Metastasis in Clinically Negative Neck Supraglottic and Glottic Cancer. *Jiurn of Pers Med.* November 2021. 25;11(12):1252.

96. **Perri F**, Fusco R, Ionna F et al. Electrochemotherapy as Palliative Treatment in Patients with Recurrent and/or Metastatic Head and Neck Tumours: European Review for Medical and Pharmacological Sciences. Jan 2022. IN PRESS.

Features Analysis for an Early Determination of the Partial Responsive Patients.

97. Anna Crispo, Piergiacomo Di Gennaro, Sergio Coluccia, Sara Gandini,

Concetta Montagnese, Giuseppe Porciello, Flavia Nocerino, Maria Grimaldi, Mariangela Tafuri, Assunta Luongo, Emanuela Rotondo, Alfonso Amore, Francesco Labonia, Serena Meola, Stefanie Marone, Giovanni Pierro, Simona Menegozzo, Leonardo Miscio, **Francesco Perri**, Maurizio Rainisio, Attilio AM Bianchi, Ernesta Cavalcanti, Marco Cascella, Egidio Celentano. A SARS-CoV-2 infection high-uptake surveillance program on healthcare workers and cancer patients in an Italian Cancer Institute. *Healthcare.* Jan 2022 IN PRESS.

98. **Perri F**, Ionna F, Salzano G, Ionna F et al. Addendum: Perri et al. Electrochemotherapy as a First Line Treatment in Recurrent Squamous Cell Carcinoma of the Oral Cavity and Oropharynx PDL-1 Negative and/or with Evident Contraindication to Immunotherapy: A Randomized Multicenter Controlled Trial. *Cancers* 2021, 13, 2210.

99. Salzano G, Togo G, Maglitto F, Borriello G, **Perri F** et al. Trans-Oral robotic surgery: 14 cases of pleomorphic adenoma of the parapharyngeal space. *Journ Craniofac Surg.* Jan 2022.

100. Lucia Cannella<sup>1</sup>, Francesco Perri\*, Claudia von Arx<sup>2</sup>, Ottavia Clemente<sup>1</sup>, Antonio Pizzolorusso<sup>1</sup>, Maurizio Di Bonito<sup>4</sup>, Alessandra Bracigliano<sup>5</sup>, Massimiliano Di Marzo<sup>6</sup>, Giuseppina Scarpati della Vittoria<sup>7</sup>, Annarosaria De Chiara<sup>8</sup>, Salvatore Tafuto<sup>1</sup>. The complex management

of the breast angiosarcoma: a retrospective study. *Oncology*. Mar 2022. IN PRESS. IF 3

101. Machine learning as decision support system (DSS) for the management of neck dissection in early-stage (cT1-T2 N0) squamous cell carcinomas of the oral tongue. Umberto Committeri, Roberta Fusco, Elio Di Bernardo, Vincenzo Abbate, Giovanni Salzano, Fabio Maglito, Giovanni Dell'Aversana Orabona, Pasquale Piombino, Paola Bonavolontà, Antonio Arena, Francesco Perri, Maria, Grazia Maglione, Sergio Venanzio Setola, Vincenza Granata, Eugenio Sorgente, Andrea Esposito, Giorgio Iaconetta, Franco Ionna, Antonella Petrillo \*, Luigi Califano. *Biology*. Mar 2022. IF 4,5

102. Cascella M, Cuomo A, Bifulco F, Perri F, Carbone F, Aprea M, Forte A, Fiore M. Could the perioperative use of opioids influence cancer outcomes after surgery? A scoping review protocol. *BMJ open*. Apr 2022. IN PRESS. IF 2

## Monografie e Abstracts

1. Chemioterapia di I linea in paziente con diagnosi di carcinoma squamoso del distretto cervico-cefalico ricorrente/metastatico con ridotto performance status.

**Perri F**

Casi clinici Persone 6. Elsevier 2011

2. Tapentadolo PR nella pratica clinica oncologica. Raffaele Costanzo, Fabiana Vitiello, Carmela Pisano, Carla Cavaliere, **Francesco Perri**, Carmela Romano, Claudia Sandomenico, Carmen Pacilio.

Terapia Evidence Based. Vol. 6 issue 3, settembre 2013.

3. L'esame clinico delle mucose orali: l'influenza sulla pratica odontoiatrica quotidiana e sulla diagnosi precoce del carcinoma squamoso del cavo orale. A Guida, **F. Perri**, S. Villano, P. Franco, F. Ionna. *Quintessenza Internazionale and Jomi* 2/19.

4. Gene expression profile differentiates short- and long-term survivors with immunotherapy in patients with recurrent/metastatic head and neck cancer. *ESMO Abstracts* 2021. Abstr no. 3381. Bossi P, **Perri F** et al.

## Capitoli di Libri di cui è autore

**Perri F**, Della Vittoria Scarpati G, Giuliano M. (2015). Carcinomas of the head and neck. *International Manual of Oncology Practice (iMOP) - Principles of Medical Oncology*,

de Mello, Ramon Andrade, Tavares, Álvaro, Mountzios, Giannis  
Springer International Publishing Switzerland, 2015  
ISBN: 978-3319216829.

**Perri F**, Della Vittoria Scarpati G, D'Ettorre E, Pisconti S. chapter:  
Emergenze in Oncologia. Manuale di Medicina di emergenza e di  
pronto soccorso - IV edizione. Balzanelli MG, Miniello - Ristagno  
- Berlot - Sinagra - Locatelli - Astuto – AAVV 2018. ISBN:  
9788893890205.

#### **Membro delle seguenti associazioni:**

- AIOCC (Associazione Italiana Oncologia Cervico Cefalica). Socio onorario
- Coordinatore” del Gruppo Oncologico Multidisciplinare (GOM) “Neoplasie Testa-Collo”
- Membro del “core team” del Gruppo Oncologico Multidisciplinare (GOM) “Tumori della Tiroide”
- Referee AIOM linee guida “tumori testa-collo”
- Referee linee guida AIOCC Tumori Testa-Collo

#### **Organizzatore e Responsabile Scientifico dei seguenti eventi ECM:**

- Preceptorship in immuno-oncologia: neoplasie testa-collo (Napoli, 10-12 Dicembre 2018) 20.8 ECM
- Preceptorship in immuno-oncologia: neoplasie testa-collo – Seconda Edizione (Napoli, 26-27 Febbraio 2020) 13.5 ECM
- Immunotherapy in Head and Neck Cancer: we can do better. Napoli 17 e 18 Dicembre 2020 (in programmazine, già approvato).
- Preceptorship on Head-Neck and Lung cancer (Webinar 3 + 3 ore) – Napoli – 7 e 8 OTTOBRE 2021 (13 ECM)

#### **Docenze varie:**

Il dott. Perri ha svolto più incarichi di docenza, per medici chirurghi iscritti a corsi di Medicina d'Urgenza e per medici specialisti in branche differenti dall'Oncologia

#### **Autore dei seguenti progetti di ricerca finanziati:**

- Valutazione di fattori prognostici e/o predittivi di risposta al trattamento in pazienti con diagnosi di SCCHN localmente avanzato. Ricerca Corrente Marzo 2011. Finanziamento euro 15'000
- Analysis of biomarkers in patients with locally advanced squamous cell carcinoma of the head and neck (APACHE). Finanziamento all'INT IRCCS Pascale di euro 70'000. Dicembre 2019
- Genetic selection of treatments in patients with locally advanced squamous cell carcinoma of the head and neck

(GATEs).Finanziamento con fondi 5 per 1000 (70'000 euro).Aprile 2020

- Additional support to cancer therapy in patients with advanced head and neck tumors. Finanziamento Fondi 5 per 1000 (90.000 Euro)

**Membro dell'Editorial Board delle seguenti riviste:**

- International Journal of Clinical Research & Trials
- Annals of Radiation Therapy and Oncology
- Journal of unexplored medical data
- Journal of Sarcoma research
- Cell Biology Research
- Biology

**ORCID number: 0000-0001-8158-7509**

**Scopus ID: 55335766600**

Il sottoscritto autorizza il trattamento dei dati personali a scopo di divulgazione scientifica

Napoli, 11/04/2023

Firma

A handwritten signature in black ink, appearing to be 'F. Ferraro', written over a horizontal line.